EGFR and non-small cell lung carcinoma: Ruiz and co-workers developed complex [Au(erlotinib)(PPh3)] (28, Figure 9) using erlotinib, a well-known EGFR inhibitor clinically employed as an anticancer drug for the treatment of patients with non-small cell lung cancer or pancreatic tumors, as an EGFR-targeting ligand [89].